Zevra Therapeutics
ZVRA
69 hedge funds and large institutions have $41.8M invested in Zevra Therapeutics in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 14 increasing their positions, 24 reducing their positions, and 8 closing their positions.
28% more capital invested
Capital invested by funds: $32.6M → $41.8M (+$9.27M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1.51% less ownership
Funds ownership: 20.92% → 19.41% (-1.5%)
4% less funds holding
Funds holding: 72 → 69 (-3)
32% less call options, than puts
Call options by funds: $6.34M | Put options by funds: $9.32M
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
42% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
+$453K |
| 2 |
Man Group
London,
United Kingdom
|
+$166K |
| 3 |
KA
Kovack Advisors
Ft. Lauderdale,
Florida
|
+$130K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
+$98K |
| 5 |
RPCONE
Retirement Planning Company of New England
Warwick,
Rhode Island
|
+$84.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$974K |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
-$479K |
| 3 |
MAM
Martingale Asset Management
Boston,
Massachusetts
|
-$338K |
| 4 |
Goldman Sachs
New York
|
-$287K |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
-$260K |
ZVRA Hedge Fund Activity: Q3 2022 in Review
69 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Zevra Therapeutics (ZVRA) for Q3 2022, worth a combined $41.8M — up 28% from $32.6M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of ZVRA and 5 opened new positions — a net loss of 3 holders — while 24 trimmed existing stakes and 14 added.
The largest buyer was HealthInvest Partners, adding an estimated $453K. The largest seller was Millennium Management, cutting an estimated $974K.
- 69 institutional investors held Zevra Therapeutics (ZVRA) as of Q3 2022, down from 72 in Q2 2022.
- Funds reported $41.8M of Zevra Therapeutics stock for Q3 2022, up 28% quarter-over-quarter.
- 5 funds opened new Zevra Therapeutics positions in Q3 2022 and 8 closed out, a net change of -3 holders.
- The largest Zevra Therapeutics buyer in Q3 2022 was HealthInvest Partners, an estimated $453K added.
- The largest Zevra Therapeutics seller in Q3 2022 was Millennium Management, an estimated $974K sold.
Based on aggregated 13F filings for Q3 2022.